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Introduction
A 54 year old female patient arrives to the emergency
department (ED) via squad complaining that 2 days ago her
lips were tingling and her face felt a little swollen but it
subsided. Today she woke up with her tongue protruding out
of her mouth, her lips, face and eyes are swollen. She does not
present with itching or urticaria. Squad personnel established
an IV, gave her intravenous (IV) Benadryl 50 mg, and 0.3 mg
subcutaneous epinephrine without any change in her
condition. The emergency medical service (EMS) also applied
oxygen at 2 liters per minute (lpm). She denies taking any
new medications or being around any possible new allergens.
She has a list of her medications and it includes aspirin,
Metformin, Simvastatin, and Lisinopril, all of which she has
been on for over a year. Vital signs are BP 184/110 mm/hg,
HR 116 bpm, RR 16/min, temporal temperature 98.2 F., and
SPO2 96% on 2 lpm of oxygen. Perplexed, the ED staff begins
their care of this anaphylactic appearing reaction.
This presentation to the emergency department has become
more common and is classic for the diagnosis of ace-inhibitor
(ACEi) related angioedema. Although it looks like a histamine
mediated response, it does not respond to typical emergency
treatments and is thought to be a bradykinin mediated
response. Angioedema is a well recognized adverse effect of
ACEi and is drug class specific, not dose specific, with
symptoms appearing from initial dosing to 10 years post
initiation. The incidence of ACEi angioedema is 0.1% to 1%
with 40% of those patients presenting months to years after
initial dosing (Winters, Rosenbaum, Vilke, & Almazroua,
2013). Tai et al. cite a female predominance of 65.7% of
retrospective reviews, the mean age was 51.8, and racial
composition was 10.9% Caucasian, 62.4% African American,
and 14.7% Hispanic (Tai, Mascaro, & Goldstein, 2010). It is
prudent that this diagnosis is recognized, the pathophysiology
understood, and treatment measures taken to control life
threatening symptoms and prevent future reactions.

Pathophysiological process
Angiotensin converting enzyme (ACE) is activated by the negative feedback loop of the reninangiotensin-aldosterone system (RAAS). Renin is stimulated in the kidneys by decreased circulating blood
pressure, serum sodium concentrations, or sensing low renal perfusion; in hypertensive patients this could be from
renal artery stenosis. Renin stimulates creation of angiotensinogen I. Angiotension I is then converted to
angiotensin II (a potent vasoconstrictor) by ACE in the lungs. Angiotension II causes vasoconstriction and the
aldosterone system to stimulate sodium and water retention in the tubules of the kidneys that contributes to the
increase in blood pressure (Appendix A). Another function of ACE is that it breaks down the proteins bradykinin,
aminopeptidase P (which helps inactivate bradykinin among its other functions), and carboxypeptidase
(Rasmussen, Mey, & Byg, 2014).
Bradykinin is produced in the kidney from kininogen and functions as potent endothelial
vasodialator. It releases nitric oxide and prostaglandins, can cause contraction of non-vascular smooth muscle in
the bronchus (bronchoconstriction), increases vascular permeability, and causes natriuresis contributing to the
drop in blood pressure (Busse & Buckland, 2012).
ACE inhibitors interfere with the RAAS by blocking the conversion of angiotensin I to angiotension II
by inhibiting ACE. The effect of lower blood pressure is that the vasoconstriction of angiotensin II is blocked and
the lack of degredation of bradykinin by ACE allows vasodialation. Eventually angiotensin II levels return to near
normal as alternative pathways are used for activation and hypertension control is maintained by bradykinin
mediated vasodialation (Lewis, 2013).
“Excess bradykinin can act on bradykinin B2 receptors, leading to a change in vascular integrity and
subsequent edema” (Norman & Holmes, 2012, p. 384). Substance P, or aminopeptidase P, also accumulates when
ACE is blocked which causes increased vascular permeability, possible activation of inflammatory processes, and
edema. The adaption or maladaption in conjunction with the increased levels of bradykinin and substance P are
thought to be the pathophysiology involved in ACEi angioedema. Histamine release may be involved in the
pathophysiology of ACEi angioedema but common treatment regimines such as antihistamines, histamine blockers,
steroids, and adrenaline do not markedly improve swelling, therefore, it is unlikely that histamine plays a
significant role in this form of angioedema (Rasmussen, Mey, & Byg, 2014).

Signs and symptoms
Angioedema (AE) is characterized by nonpitting
edema of the dermis and subcutaneous layers. The most
common sites of involvement are the tongue, lips, face,
and throat. Airway compromise is rare but drooling,
stridor, dysphagia, are symptoms that may require
primary or advanced airway control (see appendix B).
Swelling can occur in the extremities, genitalia, and
viscera of the abdomen causing abdominal pain that
may be unexplained or misdiagnosed with the routine
testing performed in the ED (Lewis, 2013). A careful
history and physical exam can help the practitioner
differentiate between a histamine mediated reaction
from a bradykinin mediated angioedema reaction.
Known recent exposure to triggers such as certain
foods, insect stings, sulfa drugs, penicillins, or other
drug classes can lead a differential diagnosis as
histamine mediated response. Rapid onset of the
swelling accompanied by hives and itching are key
indicators of an allergic reaction. Bradykinin mediated (Rasmussen,Mey,& Byg, 2014, p. 1)
angioedema is not typically accompanied by urticaria
(Cicardi, et al., 2014).

Implications for nursing care
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The most important implication for nursing care is to
recognize the life threatening airway compromise that
can accompany ACEi AE, although rare. Observation of
the patient for 12 to 24 hours in the ED or via an
admission to the hospital (Rasmussen, Mey, & Byg, 2014)
will depend on the severity of the edema and potential
for airway deterioration. The practitioner will need to
recognize that the patient needs taken off of the
offending medication, and because this type of reaction is
drug class specific, the patient cannot be put on any other
ACE inhibitors. Current research shows that patients can
usually tolerate angiotension receptor blockers (ARB’s)
but there have been some reports of a small percentage
of patients developing AE from these medications also.
ARB’s are not prescribed as much as ACEi’s which may
explain the higher rates of AE with ACEi’s.
Current recommended treatment for ACEi AE is that
the patient needs to be monitored until the swelling
resolves. A retrospective analysis by Tai et al. states that
“90% of episodes were treated with IV steroids and
histamine blockers, although not evidence-based and
ineffective” (Tai, Mascaro, & Goldstein, 2010). They also
cite that new therapies are being evaluated with
kallikrein inhibitors and bradykinin receptor antagonists
but are not approved yet in the United States for ACEi AE.
An additional treatment option that has been used with
some success is fresh frozen plasma which contains ACE
to break down bradykinin but also contains kininogen, a
bradykinin substrate (Lewis, 2013).
Many studies have tried to correlate risk factors such
as African American (AA) ethnicity, female sex, diabetes,
smoking, and alcohol use to give the practitioner
information to consider about the risk to benefit ratio for
prescribing ACEi (Lin, Levine, & Lin, 2013). AA’s show a
propensity for bradykinin sensitivity related to
polymorphisms that call for additional studies (Moholisa,
et al., 2013). Conflicting studies through this research
was that initially diabetics were thought to show some
protection against this phenomena but other metaanalysis’ showed maybe this was not accurate, and would
also need further investigation.
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Conclusion

(Rasmussen, Mey, & Byg, 2014, p. 3)

Ace inhibitors are the number one prescribed drug
class for hypertension. Since the mid 80’s when they
started gaining popularity there has been an increase in
reported ACEi AE. Patients may be on an ACEi for one
week to ten years before developing the possibly life
threatening reaction. The practitioner must be able to
recognize the signs and symptoms, understand the
pathophysiology of this bradykinin mediated edema, and
know the current recommended treatments. There
continues to be discussion about the risk factors and
increased susceptibility to develop ACEi AE and a risk to
benefit analysis for each patient. The practitioner should
provide anticipatory guidence about these risks, even
though currently <1% of patients will develop AE, so the
patient can also recognize an AE episode before it is life
threatening.

